Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Names Abgenix CEO to Board of Directors

NEW YORK, June 4 – Illumina said Monday that R. Scott Greer, chairman and CEO of Abgenix, had been elected to its board of directors.

"We are honored that Scott has agreed to join our board. He brings a solid record of leadership and accomplishment in the life sciences industry and his insight and experience will be a tremendous asset to the company," said Jay Flatley, Illumina’s CEO, said in a statement.

Greer has been CEO of Abgenix since 1996. Prior to that he held senior positions with Cell Genesys. He has a bachelors in economics from Whitman College and an M.B.A. from Harvard University.

Greer will replace Charles Hartman, who did not stand for re-election.

Illumina of San Diego develops BeadArray technology to study genetic variation and function.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.